Achieve Life Sciences (ACHV) Other Non-Current Liabilities (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Other Non-Current Liabilities came in at $1.3 million in Q1 2026, up 2.58% YoY from $1.2 million in Q1 2025, and down 18.3% on a QoQ basis from $1.6 million in Q4 2025.
Achieve Life Sciences (ACHV) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 12 years of Other Non-Current Liabilities data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 2.58% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 2.58% YoY) and the FY2025 annual result came in at $1.6 million, up 35.51% from the prior year.
- Other Non-Current Liabilities slipped to $1.3 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.6 million in Q4 2025 to a low of $528000.0 in Q4 2023.
- A 4-year average of $957750.0 and a median of $924000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities jumped 117.61% — and 2026, when it gained 2.58%.
- Tracing ACHV's Other Non-Current Liabilities over 4 years: stood at $528000.0 in 2023, then soared by 117.61% to $1.1 million in 2024, then surged by 35.51% to $1.6 million in 2025, then slipped by 18.3% to $1.3 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $1.3 million (Q1 2026), $1.6 million (Q4 2025), and $1.2 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 182.72 Mn |
| Mar 31, 2026 | 1.27 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 1.15 Mn |
| Sep 30, 2024 | 699,000.00 |
| Jun 30, 2024 | 637,000.00 |
| Mar 31, 2024 | 580,000.00 |
| Dec 31, 2023 | 528,000.00 |
| Sep 30, 2017 | 3,000.00 |
| Jun 30, 2017 | 114,000.00 |
| Mar 31, 2017 | 180,000.00 |
| Dec 31, 2016 | 232,000.00 |
| Sep 30, 2016 | 350,000.00 |
| Jun 30, 2016 | 971,000.00 |
| Mar 31, 2016 | 438,000.00 |
| Dec 31, 2015 | 1.11 Mn |
| Sep 30, 2015 | 2.84 Mn |
| Jun 30, 2015 | 2.97 Mn |
| Mar 31, 2015 | 2.54 Mn |